Biogen, Ionis win FDA approval for first spinal muscular atrophy drug

Biogen (NSDQ:BIIB) said last week that it won FDA approval for its spinal muscular atrophy treatment, Spinraza. The drug is the 1st treatment approved in the U.S. for spinal muscular atrophy, a progressive and often fatal genetic disease that causes muscle weakness in infants and toddlers.

The FDA previously granted Biogen’s application fast track designation and priority review, and Spinraza also received orphan drug designation.

Get the full story at our sister site, Drug Delivery Business News.

The post Biogen, Ionis win FDA approval for first spinal muscular atrophy drug appeared first on MassDevice.

from MassDevice http://ift.tt/2iEqULr